San Francisco-based consumer health startup Superpower, led by CEO Max Marchione, is set to commence clinical trials for BPC-157 and other peptides later this year. The announcement comes as David Gobaud, via a recent tweet, publicly inquired about the status of BPC-157 trials from @stackapp and @maxmarchione, asking, > "@stackapp @maxmarchione @maxmarchione @stackapp any update from either of you on the BPC-157 trials you're running? Did you start yet or anything?"
Superpower, which has raised $42 million, positions itself as a company focused on optimizing well-being beyond traditional "sick care." The company offers members access to comprehensive lab testing and a marketplace for supplements and peptides, aiming to provide tools for health improvement. Max Marchione has emerged as a prominent advocate for peptides, believing they represent a significant consumer health category.
The planned clinical trials for BPC-157, a compound known for its potential in reducing inflammation and improving tissue healing, will be conducted through Superpower's clinical arm, Superpower Medical Group of California. These trials are part of a broader effort to gather evidence and submit it to the FDA for approval of various peptides, including epitalon and pinealon. Superpower is also developing a long-lasting version of BPC-157 with an Australian biotech company.
The peptide market currently operates in a complex regulatory environment, with many compounds existing in a "gray zone" where they are neither explicitly banned nor fully FDA-approved. This regulatory landscape has fueled debates, such as the one between Max Marchione and biopharma veteran Martin Shkreli, concerning the efficacy, safety, and regulatory pathways for peptides. Marchione argues that the demand for these compounds is outpacing regulation and that legitimate clinical trials are crucial for safety and broader acceptance.
Max Marchione emphasizes that funding clinical trials is essential to transition peptides from anecdotal evidence to scientifically validated treatments. He believes that the current system, primarily focused on disease treatment, does not adequately address wellness and optimization. Superpower aims to bridge this gap by investing in research, leveraging its members' health data to identify eligible participants for studies, and ultimately seeking FDA approvals.
The initiation of these trials by Superpower signifies a move towards professionalizing access to peptides and addressing the regulatory challenges that have characterized the market. By conducting rigorous clinical research, Superpower hopes to expand the scientific understanding of peptides and make them more widely and safely available, potentially shaping the future of personalized health optimization.
